NOVEL COMPOUND AS KCNQ POTASSIUM CHANNEL AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF

(19)

(11)

EP 2 772 481 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	published in accordance with Art. 153(4) EPC

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	26.11.2014 Bulletin 2014/48

(43)	Date of publication:
	03.09.2014 Bulletin 2014/36

(21)	Application number: 12843367.9

(22)	Date of filing: 23.10.2012

(51)

International Patent Classification (IPC):

C07C 271/28^(2006.01)
C07C 233/43^(2006.01)
C07D 235/26^(2006.01)
A61K 31/167^(2006.01)
A61P 25/08^(2006.01)
A61P 25/28^(2006.01)
A61P 9/10^(2006.01)

C07C 269/04^(2006.01)
C07C 231/02^(2006.01)
A61K 31/27^(2006.01)
A61K 31/4184^(2006.01)
A61P 25/04^(2006.01)
A61P 25/00^(2006.01)

(86)	International application number:
	PCT/CN2012/001423

(87)	International publication number:
	WO 2013/060097 (02.05.2013 Gazette 2013/18)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

25.10.2011 CN 201110328036

(71)	Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
	Zhangjiang, Pudong Shanghai 201203 (CN)

(72)	Inventors:
	NAN, Fajun Shanghai 201203 (CN) LI, Min Shanghai 201203 (CN) GAO, Zhaobing Shanghai 201203 (CN) CHEN, Fei Shanghai 201203 (CN) ZHANG, Yangming Shanghai 201203 (CN) ZHOU, Pingzheng Shanghai 201203 (CN) HU, Haining Shanghai 201203 (CN) XU, Haiyan Shanghai 201203 (CN) LIU, Sheng Shanghai 201203 (CN)

(74)	Representative: Tischner, Oliver
	Lavoix Munich Bayerstrasse 83 80335 München 80335 München (DE)

(54)	NOVEL COMPOUND AS KCNQ POTASSIUM CHANNEL AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF

(57) The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medcine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration.